Trevi Therapeutics (TRVI) Net Income towards Common Stockholders (2018 - 2026)

Trevi Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$13.2 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 27.58% year-over-year to -$13.2 million in Q1 2026; TTM through Mar 2026 was -$45.6 million, a 3.58% increase from a year earlier, with the FY2025 full-year figure at -$42.8 million, up 10.67% from the prior year.
• Net Income towards Common Stockholders declined to -$13.2 million in Q1 2026 per TRVI's latest filing, from -$8.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$5.5 million in Q4 2022 and bottomed at -$13.2 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is -$8.3 million (2025), against an average of -$9.5 million.
• Across the five-year window, Net Income towards Common Stockholders surged 35.39% in 2022 and tumbled 72.88% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$5.5 million in 2022, then slumped by 42.07% to -$7.8 million in 2023, then plunged by 45.29% to -$11.4 million in 2024, then increased by 26.86% to -$8.3 million in 2025, then slumped by 58.73% to -$13.2 million in 2026.
• Per Business Quant, the three latest TRVI Net Income towards Common Stockholders figures stand at -$13.2 million (Q1 2026), -$8.3 million (Q4 2025), and -$11.8 million (Q3 2025).